New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

Allergic rhinitis (AR) is a chronic inflammatory respiratory disease affecting 5%–50% of the worldwide population and its prevalence is increasing (Herman 2007). In addition, AR is associated with asthma and other co-morbidities such as conjunctivitis and sinusitis. The main symptoms are nasal congestion, rhinorrea, sneezing, itching, and post-nasal drainage induced after allergen exposure by an IgE-mediated inflammation of the membranes lining the nose. AR is not a life-threatening disease, but it has been shown to have a significant impact on quality of life. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines propose a classification of AR in intermittent and persistent, each graded as mild or moderate-severe, and provide a stepwise approach to the treatment. Inhaled steroids and antihistamine are the main tools in AR therapy but more safe and effective drugs are, however, needed. Inhaled steroid ciclesonide appears to be safe and effective.

[1]  Hyun Jong Lee,et al.  Clinical Characteristics of Allergic Rhinitis According to Allergic Rhinitis and Its Impact on Asthma Guidelines , 2008, Clinical and experimental otorhinolaryngology.

[2]  E. Meltzer,et al.  Efficacy and safety of ciclesonide, 200 μg once daily, for the treatment of perennial allergic rhinitis , 2007 .

[3]  Howard S. Herman.  Once-Daily Administration of Intranasal Corticosteroids for Allergic Rhinitis: A Comparative Review of Efficacy, Safety, Patient Preference, and Cost , 2007, American journal of rhinology.

[4]  F. Hampel,et al.  Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. , 2006, The Journal of allergy and clinical immunology.

[5]  F. Hampel,et al.  Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  E. Meltzer,et al.  The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  R. Nave,et al.  Safety, Tolerability, and Exposure of Ciclesonide Nasal Spray in Healthy and Asymptomatic Subjects With Seasonal Allergic Rhinitis , 2006, Journal of clinical pharmacology.

[8]  W. Berger,et al.  Mometasone Furoate Improves Congestion in Patients with Moderate-to-Severe Seasonal Allergic Rhinitis , 2005, The Annals of pharmacotherapy.

[9]  R. Nave,et al.  Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. , 2005, Pulmonary pharmacology & therapeutics.

[10]  B. Martin.  Sexual dysfunction in patients with allergic rhinoconjunctivitis. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  R. Naclerio,et al.  Increased nasal airflow with budesonide compared with desloratadine during the allergy season. , 2005, Archives of otolaryngology--head & neck surgery.

[12]  A. Earnest,et al.  Why generic and disease‐specific quality‐of‐life instruments should be used together for the evaluation of patients with persistent allergic rhinitis , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[13]  A. Togias,et al.  Omalizumab-induced reductions in mast cell FcεRI expression and function , 2004 .

[14]  U. Wahn,et al.  Effect of anti‐immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis , 2004 .

[15]  F. Hampel,et al.  Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  M. Kaliner.  Omalizumab and the treatment of allergic rhinitis , 2004, Current allergy and asthma reports.

[17]  O. Noga,et al.  Omalizumab inhibits allergen challenge-induced nasal response , 2004, European Respiratory Journal.

[18]  F. Hampel,et al.  Dose-dependent effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis (SAR) , 2004 .

[19]  A. Togias,et al.  Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. , 2004, The Journal of allergy and clinical immunology.

[20]  S. Fderen.  Inhalers and nebulizers : which to choose and why , 2004 .

[21]  T. Casale,et al.  Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. , 2003, Allergy and asthma proceedings.

[22]  T. Casale,et al.  Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[23]  W. Berger,et al.  Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  R. Nathan,et al.  Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[25]  R. V. Wijk.  Quality of life, should we bother? , 2003 .

[26]  S. Gawchik,et al.  Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[27]  R. Gerth van Wijk.  Quality of life, should we bother? , 2003, Allergy.

[28]  J. Jolles,et al.  Relationship between allergic rhinitis, disturbed cognitive functions and psychological well‐being , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  L. Dupclay,et al.  Assessment of intranasal corticosteroid use in allergic rhinitis: benefits, costs, and patient preferences. , 2002, The American journal of managed care.

[30]  L. Salmun,et al.  24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139] , 2002, BMC family practice.

[31]  T. Sandström,et al.  The effect of omalizumab on nasal allergic inflammation. , 2002, The Journal of allergy and clinical immunology.

[32]  P. Marshall,et al.  Effects of Seasonal Allergic Rhinitis on Fatigue Levels and Mood , 2002, Psychosomatic medicine.

[33]  H. Kumbasar,et al.  Psychological status of patients with seasonal and perennial allergic rhinitis. , 2002, Journal of investigational allergology & clinical immunology.

[34]  E. Meltzer,et al.  Quality of life in adults and children with allergic rhinitis. , 2001, The Journal of allergy and clinical immunology.

[35]  K. Dietzel,et al.  Ciclesonide: An On-Site-Activated Steroid , 2001 .

[36]  M. Andersson,et al.  Dose-dependent effects of budesonide aqueous nasal spray on symptoms in a daily nasal allergen challenge model. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[37]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[38]  P. Marshall,et al.  Effects of seasonal allergic rhinitis on selected cognitive abilities. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[39]  A. Ellis,et al.  Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. , 2000, The Journal of allergy and clinical immunology.

[40]  C. Bachert,et al.  Inhaled and nasal corticosteroids: safety aspects* , 2000, Allergy.

[41]  I. Bernstein.  Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport. , 2000, The Journal of allergy and clinical immunology.

[42]  L. Borish,et al.  Economic consequences of comorbid depression, anxiety, and allergic rhinitis. , 1999, Psychosomatics.

[43]  K. Hörmann,et al.  The New Topical Steroid Ciclesonide Is Effective in the Treatment of Allergic Rhinitis , 1999, Journal of clinical pharmacology.

[44]  P. Graf.  Adverse effects of benzalkonium chloride on the nasal mucosa: allergic rhinitis and rhinitis medicamentosa. , 1999, Clinical therapeutics.

[45]  A. Harris,et al.  Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. , 1999, Allergy and asthma proceedings.

[46]  C. Laforce,et al.  Onset of action of mometasone furoate nasal spray (NASONEX®) in seasonal allergic rhinitis , 1999, Allergy.

[47]  G. Settipane,et al.  Intranasal budesonide aqueous pump spray (Rhinocort Aqua) for the treatment of seasonal allergic rhinitis. Rhinocort Aqua Study Group. , 1998, Allergy and asthma proceedings.

[48]  R. Nathan,et al.  Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[49]  C. Laforce,et al.  Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[50]  A. Foresi,et al.  Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.

[51]  M. Johnson,et al.  Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. , 1996, The Journal of allergy and clinical immunology.

[52]  P. Barnes.  Molecular mechanisms of steroid action in asthma. , 1996, The Journal of allergy and clinical immunology.

[53]  C. van Weel,et al.  Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible? , 1995, JAMA.

[54]  E. C. Smith,et al.  Comparison of twenty three nebulizer/compressor combinations for domiciliary use. , 1995, The European respiratory journal.

[55]  L. Ackerson,et al.  Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. , 1995, The Journal of allergy and clinical immunology.

[56]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[57]  G. Settipane,et al.  Triamcinolone acetonide Aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. , 1995, Clinical therapeutics.

[58]  B. Lipworth.  New perspectives on inhaled drug delivery and systemic bioactivity. , 1995, Thorax.

[59]  L. Laitinen,et al.  Airway morphology: epithelium/basement membrane. , 1994, American journal of respiratory and critical care medicine.

[60]  J. Hébert,et al.  Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. , 1994, Annals of allergy.

[61]  R. Dockhorn,et al.  Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. , 1994, The Journal of family practice.

[62]  D. Toft,et al.  Steroid receptors and their associated proteins. , 1993, Molecular endocrinology.

[63]  O. Linna,et al.  A 10‐year prognosis for childhood allergic rhinitis , 1992, Acta paediatrica.

[64]  O. Selroos,et al.  Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. , 1991, Thorax.

[65]  S. Clarke,et al.  Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. , 1991, Thorax.

[66]  R. Nathan,et al.  Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. , 1991, Annals of allergy.

[67]  G. Crompton,et al.  Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? , 1990, Thorax.

[68]  B. O’Malley,et al.  Steroid receptor family: structure and functions. , 1990, Endocrine reviews.

[69]  S. Larsson,et al.  Clinical consequences of inadequate inhalation technique in asthma therapy. , 1987, European journal of respiratory diseases.

[70]  S. Pedersen,et al.  Errors in Inhalation Technique and Efficiency in Inhaler Use in Asthmatic Children , 1986, Allergy.

[71]  J. Baskerville,et al.  Use of spacers to facilitate inhaled corticosteroid treatment of asthma. , 2015, The American review of respiratory disease.

[72]  A. Ryrfeldt,et al.  Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17α,21‐dipropionate in human liver and lung homogenate , 1984, The Journal of pharmacy and pharmacology.

[73]  E. Munch,et al.  Dose frequency in the treatment of asthmatics with inhaled topical steroid. , 1982, European journal of respiratory diseases. Supplement.